H. Schmalenberg

发表

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.

N. Schmitz, M. Baudis, M. Pfreundschuh, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer

H. Sudhoff, M. Görner, N. Rotter, 2015, PloS one.

A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharynge

H. Sudhoff, M. Görner, N. Rotter, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice

P. Schirmacher, M. Egger, J. Trojan, 2016, The Lancet. Oncology.

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial

J. Trojan, G. Folprecht, M. Schuler, 2017, Zeitschrift für Gastroenterologie.

J. Trojan, G. Folprecht, M. Schuler, 2017 .

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

A. Wein, W. Fleig, G. Kleber, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach

T. Zander, M. Egger, T. Seufferlein, 2018, Journal of Cancer Research and Clinical Oncology.

A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)

S. Hollerbach, R. Hofheinz, J. Hartmann, 2006 .

R andomized S tudy t o E valuate t he U se o f H igh-Dose T herapy as P art o f P rimary T reatment f or " Aggressive" L ymphoma

N. Schmitz, M. Baudis, M. Pfreundschuh, 2002 .

Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)

H. Sudhoff, T. Wendt, A. Dietz, 2012, BMC Cancer.

S. Hollerbach, R. Hofheinz, J. Hartmann, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.

M. Egger, J. Trojan, W. Schmiegel, 2015 .

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

T. Zander, M. Shah, J. Izbicki, 2017, BMC Cancer.

LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Gr

J. Trojan, G. Folprecht, R. Hofheinz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.

R. Wirtz, R. Hofheinz, J. Hartmann, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

P. Galle, R. Hofheinz, S. Al-Batran, 2014, BMC Cancer.

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

T. Zander, E. Maiello, R. Hofheinz, 2020 .

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

M. Pfreundschuh, M. Loeffler, M. Reiser, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Cutaneous Langerhans cell histiocytosis with subsequent development of haematological malignancies. Report of two cases.

G. Haroske, M. Kaatz, U. Wollina, 2006, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

C. Bokemeyer, S. Hollerbach, R. Hofheinz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Peter Neuhaus, Jan Langrehr, Karsten Ridwelski, 2007, JAMA.

Incidence, treatment, and outcome of parotid carcinoma, 1996–2011: a population-based study in Thuringia, Germany

P. Schlattmann, A. Mueller, T. Wendt, 2015, Journal of Cancer Research and Clinical Oncology.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

M. Egger, V. Heinemann, J. Trojan, 2019, The Lancet.

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial

M. Egger, U. Martens, S. Post, 2017, JAMA oncology.

Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011

M. Gerken, L. Heinzerling, S. Klug, 2016, BMC Cancer.

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer

S. Al-Batran, E. Jäger, S. Lorenzen, 2012, British Journal of Cancer.

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis

W. Klapper, A. Stroux, M. Herold, 2020, Annals of Hematology.

Trends in epidemiology and treatment and outcome for head and neck cancer: a population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry.

P. Schlattmann, T. Wendt, O. Guntinas-Lichius, 2014, Oral oncology.

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

O. Kuss, A. Wein, W. Fleig, 2009, British Journal of Cancer.

T. Zander, M. Shah, J. Izbicki, 2017, BMC Cancer.

Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene

A. V. van Kuilenburg, J. Maring, C. Terborg, 2008, Nucleosides, nucleotides & nucleic acids.

Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer : the AIO-FLOT 3 trial

M. Egger, U. Martens, S. Post, 2017 .

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

T. Zander, E. Maiello, R. Hofheinz, 2022, Journal of Clinical Oncology.

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at

J. Trojan, G. Folprecht, R. Hofheinz, 2017 .

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM

T. Zander, W. Bechstein, E. Maiello, 2023, International journal of cancer.

P. Galle, R. Hofheinz, S. Al-Batran, 2014, BMC Cancer.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

H. Oettle, I. Schmidt-Wolf, K. Ridwelski, 2007 .

T. Zander, M. Shah, J. Izbicki, 2017, BMC Cancer.

P. Schirmacher, M. Egger, J. Trojan, 2016, The Lancet. Oncology.

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

O. Kuss, A. Wein, W. Fleig, 2009, British Journal of Cancer.

Cutaneous Langerhans cell histiocytosis with subsequent development of haematological malignancies. Report of two cases.

G. Haroske, J. Schönlebe, E. Köstler, 2006, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

LBA27_PRDocetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)

G. Folprecht, R. Hofheinz, S. Kasper, 2017 .

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

R. Hofheinz, A. Wicki, S. Al-Batran, 2019, Journal of Clinical Oncology.